The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promotinghair health.
The conversation discusses microneedling techniques and the use of Minoxidil, copper peptides, EGF, FGF, ceramides, and hydration serums to enhance hairgrowth. It explores optimizing scalp conditions and the potential benefits of various compounds in conjunction with microneedling.
TDM-105795 showed promisinghairgrowth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
GT20029 showed promising results for hairgrowth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Extended-release oral minoxidil (VDPHL01) shows promising results for hairgrowth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.